Dr. Reddy's Laboratories S.A. et al. vs. Eye Therapies, LLC et al.
Explore the PTAB proceeding IPR2024-00563 filed by Dr. Reddy's Laboratories S.A. et al. on 2024-02-21. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2024-00563
Filing Date
2024-02-21
Accorded Filing Date
2024-02-21
Institution Decision Date
2024-09-10
Last Modified Date
2025-08-05
Proceeding Type
IPR
Termination Date
2025-07-22
Trial Status
Terminated-Settled
Parties & Counsel
Petitioner
Dr. Reddy's Laboratories S.A. et al.
Represented By
Cipriano, Linneaet alPatent Owner / Respondent
Eye Therapies, LLC et al.
Represented By
Diner, Bryanet alTribunal & Venue
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Patent Information
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 33885 | William Galliani | 650-843-5622 |
| 34262 | C Talbot | 703-456-8072 |
| 36343 | Matthew Langer | 212-497-6000 |
| 40673 | Heidi Keefe | 650-843-5000 |
| 41087 | Christopher Hutter | 703-456-8506 |
| 42669 | Brian Hopkins | 617-937-2300 |
| 42764 | Cynthia Kozakiewicz | 617-937-2300 |
| 43210 | Michael Tuscan | 202-842-7802 |
| 43255 | Bonnie Mcleod | 202-842-7800 |
| 44047 | Matthew Brigham | 650-843-5000 |
| 44546 | Kimberly Bolin | 650-543-5000 |
| 44614 | William Christiansen Ii | 206-452-8700 |
| 45409 | Heidi Erlacher | 617-937-2325 |
| 45899 | Christina Stock | 617-937-2300 |
| 47777 | Mika Mayer | 650-843-5000 |
| 47938 | William Shear | 858-550-6000 |
| 48199 | Lisa Amii | 650-843-5000 |
| 48907 | Dean Fanelli | 202-776-2050 |
| 50572 | Matthew Pavao | 617-937-2300 |
| 51909 | Carol Laherty | 206-452-8700 |
| 52292 | Connie Tong | 650-843-5000 |
| 55854 | Scott Weston | 617-937-2327 |
| 56393 | Daniel Knauss | 317-582-0173 |
| 57835 | Phillip Morton | 703-456-8000 |
| 59129 | Jeffery Wyzykowski | 202-842-7800 |
| 59307 | David Hopkins | 720-566-4063 |
| 60024 | Robert Wu | 650-943-5000 |
| 61254 | Alla Brukman | 202-842-7800 |
| 61689 | Margaret Fischofer | 703-456-8000 |
| 62305 | Jennifer Volk | 703-456-8575 |
| 63322 | Eamonn Gardner | 858-550-6086 |
| 64349 | Andrew Keith | 202-842-7800 |
| 64497 | Madhuri Roy | 650-843-5000 |
| 64911 | Mark Rogel | 206-452-8700 |
| 65144 | Samuel Whitt | 202-776-2316 |
| 65421 | Orion Armon | 720-566-4119 |
| 66418 | Jonathan Cousin | 202-842-7800 |
| 67971 | David Holly | 202-842-7800 |
| 68766 | Kenichi Hartman | 650-843-5227 |
| 68774 | Kassity Mai | 202-452-8800 |
| 69078 | Bethany Roahrig | 720-466-4178 |
| 70120 | Jeremy Binstock | 703-456-8000 |
| 70211 | Jason Valentine | 202-728-7157 |
| 70786 | Marcelo Pomeranz | 858-550-6146 |
| 70897 | Amy Motomura | 310-883-6559 |
| 71499 | Joanna Hubberts | 650-843-5098 |
| 71583 | Lesly Steinbeck | 212-479-6561 |
| 72201 | Michael Mcevoy | 202-842-7800 |
| 72629 | Anders Fernstrom | 703-456-8117 |
| 73102 | Michael Winternitz | 202-728-7034 |
| 73162 | Thomas Paxton | 617-937-2473 |
| 73384 | Chen Chen | 617-937-2384 |
| 73445 | Xiaomin Su | 202-776-2295 |
| 73668 | Aeraj Haque | 312-881-6714 |
| 73724 | Lawrence Teague | 206-452-8700 |
| 73852 | Jordan Phelan | 202-728-7066 |
| 74178 | Fraser Brown | 202-842-7850 |
| 74347 | Newman Han | 202-728-7047 |
| 75031 | Xiaozhen Yu | 202-728-7127 |
| 75736 | Xixi Sun | 617-477-2458 |
| 76165 | Fumin Shi | 202-776-2064 |
| 76239 | Dustin Knight | 571-643-5164 |
| 76259 | John Masters | 312-881-6407 |
| 76373 | Eric Owens | 212-479-6656 |
| 76421 | Meera Govindaraghavan | 202-663-7410 |
| 76534 | Mengke Mccullough | 858-550-6118 |
| 76605 | Matthew Scheideman | 202-842-7858 |
| 76692 | Asako Nagashima | 202-728-7054 |
| 76824 | Claudia Frehe | 202-842-7800 |
| 76859 | Nadeen Nsouli | 312-881-6698 |
| 76906 | Jessica Cande | 617-937-2348 |
| 77360 | Audrey Gallagher | 312-881-6717 |
| 77479 | Yin Nelson | 202-776-2088 |
| 77606 | Andrew Henderson | 425-503-7202 |
| 77755 | Scott Shaw | 650-843-5000 |
| 77802 | Robert Powers | 617-937-2490 |
| 77848 | Jordan Degayner | 312-881-6392 |
| 77930 | Mark Westwood | 650-843-5005 |
| 78052 | Alexia Dilg | 202-842-7815 |
| 78279 | Christine Dunne | 617-937-2337 |
| 78292 | Elizabeth Baez | 703-727-4270 |
| 78433 | David Schachter | 212-479-6815 |
| 78664 | Jill Kozumbo | 202-962-8384 |
| 78703 | Brendan Roach | 202-776-2180 |
| 79013 | Candace Britton | 650-543-5000 |
| 79226 | David Duron | 650-843-5604 |
| 79280 | Rachel Preston | 202-776-2315 |
| 79296 | Celeste Alvarez | 858-550-6000 |
| 79442 | Peter Chung | 703-456-8587 |
| 79458 | Sam Matthews | 617-937-2388 |
| 79575 | Felipe Guzman | 617-937-2381 |
| 79769 | Stephanie Johnson | 631-943-0991 |
| 79828 | Dou Yeon Youn | 212-479-6381 |
| 80140 | Philip Wdowiak | 312-881-6697 |
| 80181 | Natalie Hendrick | 617-937-1387 |
| 80447 | Claire Tourkin | 650-843-5138 |
| 80682 | Mengran Liu | 650-843-5114 |
| 80739 | Zhipeng Zheng | 202-776-2043 |
| 80762 | Taylor Canady | 212-479-6000 |
| 80787 | Jennifer Costigliola | 919-491-1109 |
| 80800 | Luke Sande | 617-937-2367 |
| 81166 | Nitasha Bennett | 858-550-6480 |
| 81181 | Georgia Calhoun | 858-550-6181 |
| 81333 | John Habibi | 202-776-2137 |
| 81446 | Ashley Sherrid | 206-452-8824 |
| 81515 | Nina Gu | 617-937-1459 |
| 81534 | Elif Ertem Bekdemir | 617-937-2354 |
| 81599 | Daniel Manson | 212-479-6835 |
| 81740 | Tian Yong Zheng | 206-452-8774 |
| 81797 | Rei Li | 212-479-6084 |
| 81816 | Michael Minsch Iv | 212-479-6610 |
| 81920 | Ying Yiu | 206-452-8825 |
| 81992 | Daniel Hinton | 617-937-2403 |
| 82124 | John Kozlowski | 858-550-6056 |
| 82294 | Kathleen Dinapoli | 202-842-7800 |
| 82583 | Maxwell Gonzalez | 650-843-5434 |
| 82694 | Austin Thind | 703-456-8593 |
| 82984 | Sarah Robbins | 202-776-2034 |
| 83259 | Ethan Decicco | 617-937-2312 |
| L1396 | Shanxi Feng | 202-776-2259 |
| L1408 | Gesa Junge | 212-479-6658 |
Proceeding Documents
200TERMINATION Due to Settlement After Institution of Trial 35 U.S.C. § 317; 37 C.F.R. § 42.74 TERMINATE
Joint Request to File Settlement Agreement as Business Confidential and to Keep It Separate from Patent Files MOTION
Patent Owner's Eighth Updated Exhibit List NOTICE
Joint Motion to Terminate MOTION
Ex. 3008 Motion to Terminate Exhibit
Other: Hearing transcript OTHER
Petitioners' Demonstratives OTHER
Patent Owner's Demonstratives OTHER
Joint Stipulation to Modify Schedule for Exchanging Demonstratives OTHER
Order: Setting Oral Argument ORDER
EX-2279 Deposition of John Galanis, M.D. Exhibit
Patent Owner's Sur-Reply OTHER
EX-2280 Deposition of Daniel Gil Ph.D. Exhibit
EX-2281 Deposition of Anthony Masztak Exhibit
Patent Owner's Seventh Updated Exhibit List NOTICE
Patent Owner's Notice of Deposition of Anthony M. Masztak NOTICE
Panel Change Order ORDER
Exhibit 1203 - Expert Declaration of Anthony M. Masztak in Support of Petitioners' Reply (Redacted) Exhibit
Petitioners' Request for Oral Argument OTHER
Petitioners' Motion to Seal MOTION
Petitioners' Fifth Updated Exhibit List NOTICE
Patent Owner's Request for Oral Hearing OTHER
Exhibit 1202 - Masztak CV Exhibit
Joint Stipulation to Change Due Date 3 NOTICE
E-mail authorizing counsel substitution Exhibit
Patent Owner's Amended Notice of Deposition of John C. Galanis, MD, FACS NOTICE
Patent Owner's Amended Notice of Deposition of Ivan T. Hofmann, C.P.A., C.F.F., C.L.P. NOTICE
Patent Owner's Notice of Deposition of John C. Galanis, MD, FACS NOTICE
Patent Owner's Notice of Deposition of Ivan T. Hofmann, C.P.A., C.F.F., C.L.P. NOTICE
Patent Owner's Objections to Petitioners' Exhibits OTHER
Exhibit 1194 - Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations Exhibit
Exhibit 1053 - 2022.11.13 IPR2022-00142 Noecker Deposition Transcript Exhibit
Exhibit 1198 - IPR2022-00142 Jarosz Declaration - REDACTED Exhibit
Exhibit 1179 - HG Agency Exhibit
Exhibit 1141- Torkildsen 2018 Exhibit
Exhibit 1144 - Hosten Exhibit
Exhibit 1167 - Lumify Orange Book Patent List Exhibit
Exhibit 1047 - 2025.02.19 Noecker IPR Deposition Transcript Exhibit
Exhibit 1191 - FTC Disclosures 101 for Social Media Influencers Exhibit
Exhibit 1054 - 2024.01.21 Donnenfeld PI Deposition Transcript Exhibit
Exhibit 1177 - Barry’s Find Your Strength Exhibit
Exhibit 1070 - Sklubalova 2006 Exhibit
Exhibit 1187 - FiercePharma – Bausch + Lomb kicks off TikTok Challenge for Lumify Exhibit
Exhibit 1168 - Patent Assignment for US 11596600 Exhibit
Exhibit 1139 - Ackerman 2019 Exhibit
Exhibit 1189 - PR NewsWire – Bausch + Lomb Launches #LUMIFYEyeDance Exhibit
Exhibit 1193 - TikTok OrionSisters Video Exhibit
Exhibit 1188 - 2022.11.02 IPR2022-00142 Ferris Deposition Transcript - REDACTED Exhibit
Petitioners' Motion to Seal MOTION
Exhibit 1162 - 2025.02.25 Declaration of Ivan T. Hofmann - REDACTED Exhibit
Exhibit 1192 - TikTok Allanface Video Exhibit
Exhibit 1170 - DRL Form 20-F for Fiscal Year 2023-2024 Exhibit
Exhibit 1190 - TikTok Lumify Eye Dance (November 2022) Exhibit
Exhibit 1173 - Bausch Health 2019 Q2 Earnings Call Transcript Exhibit
Exhibit 1199 - 2022.11.11 IPR2022-00142 Jarosz Deposition Transcript Exhibit
Exhibit 1045 - 2025.02.13 Stamer IPR Deposition Transcript Exhibit
Exhibit 1184 - Wavemaker Global – Our Work Exhibit
Petitioners' Reply REPLYTOOPP
Exhibit 1169 - Lumify Label Exhibit
Exhibit 1129 - IPR2022-00142 Noecker Declaration - REDACTED Exhibit
Exhibit 1163 - CV of Ivan T. Hofmann Exhibit
Exhibit 1200 - Barry’s Instagram Exhibit
Exhibit 1178 - HG 2019 Muse Creative Awards Exhibit
Exhibit 1201 - US Patent No. 9,259,425 Exhibit
Exhibit 1044 - 2025.02.06 Donnenfeld IPR Deposition Transcript Exhibit
Exhibit 1048 - 2025.01.28 Williams IPR Deposition Transcript Exhibit
Exhibit 1175 - Bausch Health 2021 Q4 Earnings Call Transcript Exhibit
Exhibit 1147 - 2025.02.25 Reply Declaration of John C. Galanis Exhibit
Exhibit 1058 - ARVO Glossary Exhibit
Exhibit 1181 - MUSE Awards 2019 Silver Winner Information Exhibit
Exhibit 1172 - Bausch Fourth Quarter 2018 Earnings Call Transcript Exhibit
Exhibit 1195 - Event Marketer Coachella 2024 Experimental Marketing Exhibit
Exhibit 1031 - 2023.12.31 Gil PI Deposition Transcript Exhibit
Exhibit 1186 - LumifyEyes – Lumify Eye Illuminations Exhibit
Exhibit 1183 - Wavemaker Global – Two Gold Effies Exhibit
Exhibit 1185 - Businesswire – Lumify Eye Illuminations Exhibit
Exhibit 1174 - Bausch Health 2020 Q4 Earnings Call Transcript Exhibit
Exhibit 1182 - MUSE Awards 2019 Rose Gold Winner Information Exhibit
Exhibit 1069 - Sklubalova 2005 Exhibit
Exhibit 1059 - Decoding Your Prescriptions: Understanding Pharmacy Abbreviations Exhibit
Exhibit 1180 - MUSE Awards Exhibit
Exhibit 1072 - 2024.02.19 Williams PI Deposition Transcript Exhibit
Exhibit 1171 - IPR2022-00142 Declaration of Ivan T. Hofmann - REDACTED Exhibit
Exhibit 1140 - McLaurin 2018 Exhibit
Patent Owner's Updated Mandatory Notices NOTICE
ORDER Denying without Prejudice Petitioner’s Motion for Additional Discovery 37 C.F.R. § 42.51(b)(2)(i) ORDER
Petitioners' Updated Mandatory Notices NOTICE
ORDER Granting Patent Owner’s Motion for Pro Hac Vice Admission of Matthew J. Luneack 37 C.F.R. § 42.10 ORDER
Ex. 3005 Exhibit
Ex. 3006 Exhibit
Patent Owner's Sixth Updated Exhibit List NOTICE
EX-2277 Order Granting Motion to Stay Exhibit
Exhibit 1038 - Declaration of Timothy J. Beavers in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel Under 37 C.F.R. Section 42.10(c) Exhibit
EX-2276 Email chain regarding Depositions Exhibit
Petitioners' Fourth Updated Exhibit List NOTICE
EX-2278 Email chain regarding cross use agreement Exhibit
Patent Owner's Opposition to Petitioners' Motion for Additional Discovery OPPOSITION
Petitioners' Unopposed Notice of Intent to Designate Provisionally Recognized PTAB Attorney Timothy J. Beavers as Back Up Counsel Under 37 C.F.R. Section 42.10(c) NOTICE
EX-2275_Declaration of Matthew J. Luneack in Support of Motion for Admission Pro Hac Vice Exhibit
Patent Owner's Fifth Updated Exhibit List NOTICE
Patent Owner's Motion for Admission Pro Hac Vice of Matthew J. Luneack MOTION
Petitioners' Third Updated Exhibit List NOTICE
Petitioners' Unopposed Notice of Intent to Designate Provisionally Recognized PTAB Attorney Elaine Blais as Back Up Counsel Under 37 C.F.R. Section 42.10(c) NOTICE
Exhibit 1036 - Declaration of Elaine H. Blais in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel Under 37 C.F.R. Section 42.10(c) Exhibit
Petitioners' Notice of Deposition of Robert J. Noecker NOTICE
Exhibit 1033 - Declaration of Robert Frederickson III in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel Under 37 C.F.R. Section 42.10(c) Exhibit
Petitioners' Unopposed Notice of Intent to Designate Provisionally Recognized PTAB Attorney Robert Frederickson III as Back Up Counsel Under 37 C.F.R. Section 42.10(c) NOTICE
Exhibit 1039 - District Court Protective Order Exhibit
Petitioners' Motion for Additional Discovery MOTION
Ex. 3004 Exhibit
Petitioners' Second Updated Exhibit List NOTICE
Petitioners' Notice of Deposition of Dr. Daniel Gil NOTICE
Petitioners' Notice of Deposition of Dr. Eric Donnenfeld NOTICE
Petitioners' Notice of Deposition of John Ferris NOTICE
Petitioners' Notice of Deposition of John Jarosz NOTICE
Petitioners' Notice of Deposition of Kurt R. Karst NOTICE
Petitioners' Notice of Deposition of Dr. Robert Williams III NOTICE
Exhibit 3003 Exhibit
Petitioners' Notice of Deposition of Dr. W. Daniel Stamer NOTICE
Petitioners' Updated Mandatory Notices NOTICE
Petitioners' Updated Power of Attorney NOTICE
[Amended] Patent Owner's Response RESPONSE
EX-2271 Plaintiffs' Opening Markman Brief (Amended) Exhibit
Patent Owner's Fourth Updated Exhibit List NOTICE
Exhibit 3002 Exhibit
Petitioners' Objections to Patent Owner's Evidence Submitted with Patent Owner's Response OTHER
EX-2203 (target.com) Exhibit
EX-2048 Alphagan P 0.1% Chemistry Review Exhibit
EX-2089 Lee 2017 Exhibit
EX-2144 (Lumify NDA Summary) Exhibit
EX-2069 Lumify ECP A&U Report 2020 (Public) Exhibit
EX-2266 FDA, Rulemaking History for OTC Ophthalmic Drug Products Exhibit
EX-2139 (Lumify Feb 2019 Supp) Exhibit
EX-2096 U.S. Patent No. 3,890,319 (Pfizer) Exhibit
EX-2267 FDA, Regulatory Procedures Manual, Chapter 4-Advisory Actions Exhibit
EX-2254 FDA Guid, Adverse-Reactions-Section-of-Label (2006) Exhibit
EX-2155 (accessdata.fda.gov NDA 020485 products) Exhibit
EX-2143 (Lumify NDA Approval) Exhibit
EX-2211 drreddys.com-Dr. Reddy’s Laboratories–who are we Exhibit
EX-2177 (ir.bauschhealth.com Lumify approval) Exhibit
EX-2202 (rohtoeyedrops.com-Redness Reliever) Exhibit
EX-2091 Acheampong 2002 Exhibit
EX-2251 FDA, Draft Guid, Appls-Covered-by-Sect-505(b)(2) (1999) Exhibit
EX-2230_Declaration of John Ferris (600 Patent - Public) Exhibit
EX-2272 Decl of Dr. Trattler ISO Plaintiffs' Opening Markman (600 patent) Exhibit
EX-2255 FDA Guid, ANDAs-Pharma-Solid-Polymorphism (2007) Exhibit
EX-2161 (cleareyes.com all redness relief) Exhibit
EX-2088 Rowland 1995 Exhibit
EX-2179 (ir.nielsen.com) Exhibit
EX-2075 LUMIFY INCREMENTALITY (Public) Exhibit
EX-2253 FDA, Guid Doc Search (OTC) Exhibit
EX-2065 LUMIFY® Redness Reliever Eye Drops _ Bausch + Lomb Exhibit
EX-2185 2024.11.15-optometricmanagment.com-How to Maximize Exhibit
EX-2116 Lai Exhibit
EX-2118 AU 2002254265 Exhibit
Patent Owner's Motion to Seal and Entry of Stipulated Proposed Protective Order MOTION
EX-2190 pitchbook.com Exhibit
EX-2059 2019 NewBeauty Award Winners_ Best Innovations Exhibit
EX-2239 (Rocklatan Label) Exhibit
EX-2123 Ching and Ishihara 2012 Exhibit
EX-2081 Huang Exhibit
EX-2232 Drug Appl Process for Nonprescription Drugs Exhibit
EX-2193 (prnewswire.com -Nielsen BASES) Exhibit
EX-2084 Middleton Auvelity Exhibit
EX-2041 Allergan v. Sandoz 14-275 opinion Exhibit
EX-2108 Alphagan 0.2% Monograph Exhibit
EX-2178 (ir.bauschhealth.com name change) Exhibit
EX-2171 (eyewire.news) Exhibit
EX-2043 Drugs@FDA - Alphagan P 0.15% Exhibit
EX-2047 Alphagan P 0.15% Chemistry Review Exhibit
EX-2172 (fda.report Bausch filings) Exhibit
EX-2101 Uretmen 2003 Exhibit
EX-2238 (Oxervate Label) Exhibit
EX-2247 FDA, Approval Letter, RID MOUSSE (NDA 021043) (Mar. 7, 2000) Exhibit
EX-2187 2024.11.15-patents.bausch.com-Bausch Patents Exhibit
EX-2110 Schuman 1997 Exhibit
EX-2055 (prnewswire.com -Nielsen BASES) Exhibit
EX-2186 (optometrytimes.com) Exhibit
EX-2036 Alphagan P (0.1%) Approval Letter 2005 Exhibit
EX-2191 (prestigebrands.com) Exhibit
EX-2165 (cleareyes.com Directions) Exhibit
EX-2105 13-100-0005 Clinical Study Report Excerpt PUBLIC Exhibit
EX-2183 (mckinsey.com) Exhibit
EX-2236 (Rhopressa Label) Exhibit
EX-2083 Picture of an Eye Exhibit
EX-2216 3q24-bausch-lomb-earnings-presentation (replacement) Exhibit
EX-2109 Dillon Pena_ LUMIFY Lover 2021 Exhibit
EX-2140 (Lumify Mar 2020 Supp) Exhibit
EX-2098 OTC Drug Review Process _ OTC Drug Monographs _ FDA Exhibit
EX-2103 10-100-0008 Clinical Study Report Excerpt PUBLIC Exhibit
EX-2257 FDA Guid, Innovative-Approaches (2018) Exhibit
EX-2049 21 CFR Part 330_Part 1 of 2 Exhibit
EX-2094 Belmonte 2004 Exhibit
EX-2212 New-2024.11.17-drreddys.com-contact-us (princeton nj) Exhibit
EX-2268 PhRMA, Research and Development Policy Framework Exhibit
EX-2256 FDA Guid, Expedited Progs for Serious Conditions (2014) Exhibit
EX-2127 (Samuelson and Nordhause) updated_Part 2 of 2 Exhibit
EX-2176 (ir.bauschhealth.com Lumify launch) Exhibit
EX-2141 (Lumify Nov 2021 Supp) Exhibit
EX-2087 Pandit 2007 Exhibit
Download Proceeding Documents
Case IPR2024-00563 • 200 documents
Preparing ZIP Archive
Email verified! Bundling proceeding documents from USPTO. Your download will start automatically in a few seconds...